Rare disease player rakes in a meaty $81M in Spain's biggest ever private biotech fundraise
Funding rounds in the United States for the life sciences industry often dwarf financing in Europe. Looks like rare disease biotech Sanifit is an anomaly. On Wednesday, the Spanish drug developer unveiled a nearly $81 million bounty — Spain’s largest-ever private biotech fundraise — ahead of a pivotal study for its lead experimental drug.
Sanifit, which was spun out of the University of the Balearic Islands in 2007, is working on a treatment for calciphylaxis, a rare disease characterized by calcium accumulation in small blood vessels of the fat and skin tissues — which lead to blood clots, skin ulcers and potentially life-threatening infections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.